GSK’s RSV Vaccine Nabs First EU Approval of its Kind

Glaxo-Smith Klein (GSK) has received approval by the European Commission for its respiratory syncytial virus (RSV) vaccine Arexvy in adults aged 60 and up. This marks the first EU approval of a vaccine for RSV vaccine. This puts them ahead of Pfizer, whose vaccine Abrysvo has yet to be approved in the EU.

According to Phil Taylor, “RSV leads to over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in the 60-plus age bracket every year in Europe, according to GSK. GSK’s approval is based on the phase 3 AReSVi-006 study, showed an estimated 83% protection against RSV-confirmed lower respiratory tract infections for at least six months.”

To read more, click here.

(Source: PharmaPhorum, June 7^th, 2023)